Acute effects of resveratrol on circulatory function in obese people with elevated blood pressure.

Not Applicable

Completed

• Conditions: Endothelial vasodilator function; Blood pressure response to exercise; Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system; Cardiovascular - Hypertension

• Registration Number: ACTRN12609000023257
• Lead Sponsor: Professor Peter Howe

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-01-12
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Men or post-menopausal women (self reported cessation of menses for at least 12 months) aged 30 - 70 years.
b) Volunteers will be overweight or obese (Body mass index (BMI) ranging from 25kg/m2 to 35kg/m2), and
c) have high-normal BP or untreated mild primary hypertension (systolic BP 130-160 mmHg or Diastolic BP 85-100 mmHg)
d) but are otherwise healthy.

Volunteers will provide a blood sample on the first day of testing to assess blood chemistry, coagulation and hematology outcomes to ensure there are no underlying medical conditions that would influence the study outcomes.

Exclusion Criteria

a) have cardiovascular disease, renal disease or diabetes
b) take BP lowering medication
c) have any other medical condition or treatments (including supplements) which, in the opinion of the investigators, may influence the outcome of the study
d) smoke or use nicotine replacement therapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Degree of change in vasodilator function assessed by flow mediated dilatation in the brachial artery.[There will be four time points which will occur one week apart. At each visit testing will commence one hour after consumption of each dose of resveratrol or placebo.]

Secondary Outcome Measures

Name	Time	Method
Blood pressure responses to exercise will be assessed continuously using a Finapres blood pressure monitor, which measures blood pressure non-invasively through the finger.[There will be four time points which will occur one week apart. At each visit testing will commence one hour after consumption of each dose of resveratrol or placebo.];A small blood sample will be taken one hour after the consumption of each dose of resveratrol or placebo to assess plasma levels of resveratrol.<br>Blood samples will be sent to DSM in Switzerland for analysis.[There will be four time points which will occur one week apart. At each visit testing will commence one hour after consumption of each dose of resveratrol or placebo.]